Nephrology: what's new in 2022
Severe cases of IGA nephropathy might benefit from corticosteroid therapy. Inflimidase may be a promising treatment of Goodpasture disease. SGLT2 inhibitors and acetazolamide act synergistically with loop diuretics in the treatment of acute cardiac failure. In hemodialysis, use of lung ultrasound to...
Gespeichert in:
| Veröffentlicht in: | Revue médicale suisse 2023-02, Vol.19 (812), p.229 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | fre |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 812 |
| container_start_page | 229 |
| container_title | Revue médicale suisse |
| container_volume | 19 |
| creator | De Seigneux, Sophie Haidar, Fadi Jaques, David Berchtold, Lena Olivier, Valérie Saudan, Patrick |
| description | Severe cases of IGA nephropathy might benefit from corticosteroid therapy. Inflimidase may be a promising treatment of Goodpasture disease. SGLT2 inhibitors and acetazolamide act synergistically with loop diuretics in the treatment of acute cardiac failure. In hemodialysis, use of lung ultrasound to determine the ultrafiltration seems to decrease hospitalizations due to acute heart failure but does not reduce patient-centered outcomes. Icodextrin may mitigate the loss of ultrafiltration in PD patients who are carriers of the Aquaporin I promotor TT genotype. MICA-antibodies have an impact on the risk of graft rejection. Xenotransplantation may become a reality. |
| doi_str_mv | 10.53738/REVMED.2023.19.812.229 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_36723654</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>36723654</sourcerecordid><originalsourceid>FETCH-pubmed_primary_367236543</originalsourceid><addsrcrecordid>eNpjYJA3NNAzNTY3ttAPcg3zdXXRMzIwMtYztNSzMDTSMzKyZGHgNDQzM9C1NDa35GDgLS7OMgACM0NjIyNjdgYOYzNzI2MzUxNOBjm_1IKMovyc_PRKK4XyjMQS9WKFvNRyhcw8BaCRRjwMrGmJOcWpvFCam0HOzTXE2UO3oDQpNzUlvqAoMzexqDIeZqAxQQUA4ywv2g</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Nephrology: what's new in 2022</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>De Seigneux, Sophie ; Haidar, Fadi ; Jaques, David ; Berchtold, Lena ; Olivier, Valérie ; Saudan, Patrick</creator><creatorcontrib>De Seigneux, Sophie ; Haidar, Fadi ; Jaques, David ; Berchtold, Lena ; Olivier, Valérie ; Saudan, Patrick</creatorcontrib><description>Severe cases of IGA nephropathy might benefit from corticosteroid therapy. Inflimidase may be a promising treatment of Goodpasture disease. SGLT2 inhibitors and acetazolamide act synergistically with loop diuretics in the treatment of acute cardiac failure. In hemodialysis, use of lung ultrasound to determine the ultrafiltration seems to decrease hospitalizations due to acute heart failure but does not reduce patient-centered outcomes. Icodextrin may mitigate the loss of ultrafiltration in PD patients who are carriers of the Aquaporin I promotor TT genotype. MICA-antibodies have an impact on the risk of graft rejection. Xenotransplantation may become a reality.</description><identifier>ISSN: 1660-9379</identifier><identifier>DOI: 10.53738/REVMED.2023.19.812.229</identifier><identifier>PMID: 36723654</identifier><language>fre</language><publisher>Switzerland</publisher><subject>Heart Failure - therapy ; Hospitalization ; Humans ; Nephrology ; Renal Dialysis ; Ultrafiltration</subject><ispartof>Revue médicale suisse, 2023-02, Vol.19 (812), p.229</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36723654$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Seigneux, Sophie</creatorcontrib><creatorcontrib>Haidar, Fadi</creatorcontrib><creatorcontrib>Jaques, David</creatorcontrib><creatorcontrib>Berchtold, Lena</creatorcontrib><creatorcontrib>Olivier, Valérie</creatorcontrib><creatorcontrib>Saudan, Patrick</creatorcontrib><title>Nephrology: what's new in 2022</title><title>Revue médicale suisse</title><addtitle>Rev Med Suisse</addtitle><description>Severe cases of IGA nephropathy might benefit from corticosteroid therapy. Inflimidase may be a promising treatment of Goodpasture disease. SGLT2 inhibitors and acetazolamide act synergistically with loop diuretics in the treatment of acute cardiac failure. In hemodialysis, use of lung ultrasound to determine the ultrafiltration seems to decrease hospitalizations due to acute heart failure but does not reduce patient-centered outcomes. Icodextrin may mitigate the loss of ultrafiltration in PD patients who are carriers of the Aquaporin I promotor TT genotype. MICA-antibodies have an impact on the risk of graft rejection. Xenotransplantation may become a reality.</description><subject>Heart Failure - therapy</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Nephrology</subject><subject>Renal Dialysis</subject><subject>Ultrafiltration</subject><issn>1660-9379</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpjYJA3NNAzNTY3ttAPcg3zdXXRMzIwMtYztNSzMDTSMzKyZGHgNDQzM9C1NDa35GDgLS7OMgACM0NjIyNjdgYOYzNzI2MzUxNOBjm_1IKMovyc_PRKK4XyjMQS9WKFvNRyhcw8BaCRRjwMrGmJOcWpvFCam0HOzTXE2UO3oDQpNzUlvqAoMzexqDIeZqAxQQUA4ywv2g</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>De Seigneux, Sophie</creator><creator>Haidar, Fadi</creator><creator>Jaques, David</creator><creator>Berchtold, Lena</creator><creator>Olivier, Valérie</creator><creator>Saudan, Patrick</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20230201</creationdate><title>Nephrology: what's new in 2022</title><author>De Seigneux, Sophie ; Haidar, Fadi ; Jaques, David ; Berchtold, Lena ; Olivier, Valérie ; Saudan, Patrick</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_367236543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2023</creationdate><topic>Heart Failure - therapy</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Nephrology</topic><topic>Renal Dialysis</topic><topic>Ultrafiltration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Seigneux, Sophie</creatorcontrib><creatorcontrib>Haidar, Fadi</creatorcontrib><creatorcontrib>Jaques, David</creatorcontrib><creatorcontrib>Berchtold, Lena</creatorcontrib><creatorcontrib>Olivier, Valérie</creatorcontrib><creatorcontrib>Saudan, Patrick</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Revue médicale suisse</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Seigneux, Sophie</au><au>Haidar, Fadi</au><au>Jaques, David</au><au>Berchtold, Lena</au><au>Olivier, Valérie</au><au>Saudan, Patrick</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nephrology: what's new in 2022</atitle><jtitle>Revue médicale suisse</jtitle><addtitle>Rev Med Suisse</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>19</volume><issue>812</issue><spage>229</spage><pages>229-</pages><issn>1660-9379</issn><abstract>Severe cases of IGA nephropathy might benefit from corticosteroid therapy. Inflimidase may be a promising treatment of Goodpasture disease. SGLT2 inhibitors and acetazolamide act synergistically with loop diuretics in the treatment of acute cardiac failure. In hemodialysis, use of lung ultrasound to determine the ultrafiltration seems to decrease hospitalizations due to acute heart failure but does not reduce patient-centered outcomes. Icodextrin may mitigate the loss of ultrafiltration in PD patients who are carriers of the Aquaporin I promotor TT genotype. MICA-antibodies have an impact on the risk of graft rejection. Xenotransplantation may become a reality.</abstract><cop>Switzerland</cop><pmid>36723654</pmid><doi>10.53738/REVMED.2023.19.812.229</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1660-9379 |
| ispartof | Revue médicale suisse, 2023-02, Vol.19 (812), p.229 |
| issn | 1660-9379 |
| language | fre |
| recordid | cdi_pubmed_primary_36723654 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Heart Failure - therapy Hospitalization Humans Nephrology Renal Dialysis Ultrafiltration |
| title | Nephrology: what's new in 2022 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A30%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nephrology:%20what's%20new%20in%202022&rft.jtitle=Revue%20m%C3%A9dicale%20suisse&rft.au=De%20Seigneux,%20Sophie&rft.date=2023-02-01&rft.volume=19&rft.issue=812&rft.spage=229&rft.pages=229-&rft.issn=1660-9379&rft_id=info:doi/10.53738/REVMED.2023.19.812.229&rft_dat=%3Cpubmed%3E36723654%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36723654&rfr_iscdi=true |